Trials
18 active
31 in total · 22 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Sublingual film containing 60 Micrograms BXCL501 Europe Only”In the company’s words, NCT05025605 on ClinicalTrials.gov
- Tested for
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II
- Main trialPhase 1
- “This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.”In the company’s words, NCT05025605 on ClinicalTrials.gov
- Other names
- Dexmedetomidine
Other drugs for Schizophrenia
- CariprazineAbbVie · Phase 3
- EvenamideNewron Pharmaceuticals SPA · Phase 3
- LB-102LB Pharmaceuticals Inc. · Phase 3
- B2227Bostal Drug Delivery Co., Ltd · Phase 2/3
- Brexpiprazole for ER injectionBostal Drug Delivery Co., Ltd · Phase 2/3
- LYBALVIAlkermes, Inc. · Phase 3
Coming up1
- 31 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials31
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Jul 2027 | Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder | |
| Phase 3Completed | 21 Apr 2023 | Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) | |
| Phase 3Terminated | 11 Sep 2023 | Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) | |
| Phase 3Completed | 15 Aug 2025 | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) | |
| Phase 2Withdrawn | 21 Feb 2022 | Study of BXCL501 In Agitation Associated With Delirium in ICU Patients | |
| Phase 2Terminated | 1 Apr 2022 | An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia | |
| Phase 2Completed | 7 Oct 2025 | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder | |
| Phase 1/2Completed | 24 Jan 2022 | Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia | |
| Phase 1Completed | 31 Jul 2019 | Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia | |
| Phase 4Authorised | not given | Effects of an Opioid Sparing Care Pathway for Patients undergoing Obesity Surgery | |
| Phase 3/4Not authorised | not given | Comparison of different doses of perineural dexmedetomidine as adjuvans to ropivacaine 0,67% for interscalene plexus block in association with 10 mg intravenous dexamethasone: a single center, double blinded, randomised controlled trial. | |
| Phase 3/4Ended | not given | Comparison of different doses of perineural dexmedetomidine as adjuvans to ropivacaine 0,67% for interscalene plexus block in association with 10 mg intravenous dexamethasone: a single center, double blinded, randomised controlled trial. | |
| Phase 2Authorised | not given | Influence of Dexmedetomidine on the Human Glymphatic Cerebrospinal Fluid Flow, Neural Activity and Cerebral Blood Flow in Functional Magnetic Resonance Imaging (GlymphDex) | |
| Phase 2Authorised | not given | Pain Relief at Screening for Retinopathy of Prematurity - The PROPER study | |
| Phase 3Authorised | not given | Double blind, multicenter, randomized, controlled trial of dexmedetomidine vs placebo in premature neonates receiving invasive ventilation | |
| Phase 2/3Authorised | not given | Advancing the quality of treatment and care for acute agitation in emergency psychiatry | |
| Phase 3/4Authorised | not given | Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomised controlled trial | |
| Phase 4Authorised | not given | The effect of nocturnal dexmedetomidine on postoperative sleep quality and fatigue after major surgery in elderly patients: DEXSLEEP study | |
| Phase 3Ended | not given | Impact of post-Acute respiratory distress syndrome COVID sedation on late neuroinflammation (PET-DEXDOCOVID) | |
| Phase 3Ended | not given | Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children | |
| Phase 2Authorised | not given | Intravenous dexmedetomidine as an adjuvant to locoregional anesthesia in pediatric surgery: a prospective, randomized, double-blind, placebo-controlled study. DEXPED | |
| Phase 4Authorised | not given | Intranasal dexmedetomidine sedation and analgesia during minor procedures in the pediatric emergency room: Randomized double-blinded clinical trial | |
| Phase 3Authorised | not given | Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled trial | |
| Phase 4Halted | not given | Opioid-Free General Anesthesia Compared to Opioid-Based General Anesthesia for the Reduction of Postoperative Nausea and Vomiting in Patients Undergoing Robotic Bariatric Surgery - ANGELO Study | |
| Phase 2Authorised | not given | The use of intranasal dexmedetomidine for pediatric sedation in non-invasive radiological procedures (CTMS 004321) Assessing the efficacy and safety profile of intranasal dexmedetomidine for procedural sedation in radiological procedures in children with a prospective exploratory interventional monocentric study in a tertiary center in Antwerp (Belgium) | |
| Phase 4Authorised | not given | Incidence and severity of postoperative delirium associated with Dexmedetomidine sedation during femur osteosynthesis in the elderly population | |
| Phase 4Authorised | not given | Is magnesium sulfate an alternative with an analgesic and safety profile equivalent to dexmedetomidine as an adjuvant to ropivacaine in erector block in mastectomy? | |
| Phase 3Authorised | not given | Efficacy of Dexmedetomidine on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Double-Blind Randomized Controlled Trial with Heart Rate Variability and Electroencephalography-Guided Anesthesia | |
| Phase 3Authorised | not given | ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled trial | |
| Phase 3/4Authorised | not given | OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surgery | |
| Phase 2Authorised | not given | DEXmedetomidine to Improve Neurologic Injury of patients after out-of-hospital cardiac arrest – a phase II randomized, double blind, placebo-controlled, parallel group trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026